Haleon PLC Sponsored ADR $HLN Position Increased by Synovus Financial Corp

Key Points

• Synovus Financial Corp increased its position in Haleon PLC by 202.9% during the first quarter, holding a total of 474,011 shares valued at approximately $4.88 million.
• Haleon recently announced a semi-annual dividend of $0.0555 per share, representing a yield of 190%, an increase from the previous dividend of $0.05.
• Analysts have varying recommendations for Haleon, with BNP Paribas upgrading the stock to a "strong-buy" rating and setting a target price of $13.40.

Synovus Financial Corp raised its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 202.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 474,011 shares of the company's stock after buying an additional 317,544 shares during the period. Synovus Financial Corp's holdings in Haleon were worth $4,878,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HLN. Bartlett & CO. Wealth Management LLC raised its holdings in Haleon by 135.9% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock valued at $27,000 after buying an additional 1,491 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in Haleon during the first quarter valued at about $29,000. Deutsche Bank AG raised its holdings in Haleon by 267.8% during the first quarter. Deutsche Bank AG now owns 3,126 shares of the company's stock valued at $32,000 after buying an additional 2,276 shares in the last quarter. Continuum Advisory LLC raised its holdings in Haleon by 152.4% during the first quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock valued at $49,000 after buying an additional 2,870 shares in the last quarter. Finally, Alpine Bank Wealth Management bought a new position in Haleon during the first quarter valued at about $56,000. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Performance

HLN stock opened at $9.8050 on Monday. The company has a 50 day moving average price of $9.93 and a 200 day moving average price of $10.22. The stock has a market capitalization of $43.97 billion, a PE ratio of 25.14, a price-to-earnings-growth ratio of 2.90 and a beta of 0.23. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63.

Haleon Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Thursday, September 18th. Investors of record on Friday, August 15th will be paid a $0.0555 dividend. This represents a yield of 190.0%. The ex-dividend date of this dividend is Friday, August 15th. This is a boost from Haleon's previous semi-annual dividend of $0.05. Haleon's dividend payout ratio (DPR) is currently 28.21%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HLN. BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price on the stock in a research report on Tuesday, May 27th. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a research report on Friday, May 9th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Finally, Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.